ATNMActinium Pharmaceuticals, Inc.

1.100USD-2.65%Mkt Cap: 34.51M $P/E: 3.14

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a…

Key Statistics

Company
Market Cap34.51M $
Enterprise Value-546.42K $
Revenue (TTM)35.09M $
Gross Profit35.09M $
Net Income (TTM)-33.89M $
Revenue/Share1.123 USD
Last Price1.100 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees27
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)3.14
P/E (Forward)-2.10
PEG
EV/EBITDA-0.06
EV/Revenue-0.02
P/S0.98
P/B1.14
EPS (TTM)0.35
EPS (Forward)-0.53
52W Range
0.735134% of range1.806
52W High1.806 USD
52W Low0.7351 USD
Profitability
Gross Margin100.00%
Oper. Margin78.76%
EBITDA Margin27.90%
Profit Margin-37652.22%
ROE-432.56%
ROA-65.45%
Growth
Revenue Growth
Earnings Growth
Cash Flow & Leverage
Operating CF-24.58M $
CapEx (TTM)104.00K $
FCF Margin20.36%
FCF Yield20.70%
Net Debt-35.13M $
Net Debt/EBITDA-3.59
Balance Sheet
Debt/Equity0.22
Current Ratio4.08
Quick Ratio3.94
Book Value/Sh0.9640 USD
Cash/Share1.160 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay DateAug 11, 2020
Splits
Last Split1:30
Split DateAug 11, 2020
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.500 USD
Upside (mean)+218.2%
Target Range2.000 USD5.000 USD
$2.000+218.2% to mean$5.000
# Analysts4
Ownership
Shares Out.31.37M
Float31.25M
Insiders2.34%
Institutions20.53%
Short Interest
Short Ratio9.0d
Short % Float2.52%
Short % Out.2.51%
Shares Short786.98K
Short (prev mo.)936.71K
Technical
SMA 500.9383 (+17.2%)
SMA 2001.175 (-6.4%)
Beta0.02
S&P 52W Chg19.18%
Avg Vol (30d)137.39K
Avg Vol (10d)236.60K
Technical Indicators
RSI (14)68.4
MACD0.0323
MACD Signal-0.0108
MACD Hist.+0.0430
BB Upper1.107 USD
BB Middle0.8803 USD
BB Lower0.6533 USD
BB Width51.57%
ATR (14)0.0602 USD
Vol Ratio (20d)0.85x